Immunostimulants for Malignant Gliomas

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 53-65

  Butowski, Nicholas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokine; Glioblastoma multiforme; Immunostimulant; Immunotherapy; Novel therapy

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; CANCER VACCINE; CARMUSTINE; CDX 110; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HILTONOL; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; LOMUSTINE; PATTERN RECOGNITION RECEPTOR; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERLEUKIN 12; RETROVIRUS VECTOR; TEMOZOLOMIDE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BRAIN EDEMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; COLON CANCER; CYTOKINE RELEASE; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG TOLERABILITY; EFFECTOR CELL; FATIGUE; GENE TRANSFER; GENETIC TRANSDUCTION; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; LIVER CANCER; LOW DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOMA; MELANOMA; NAUSEA; NEURAL STEM CELL; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIOMA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR UPREGULATION; RECOMBINANT DNA TECHNOLOGY; REVIEW; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRAIN NEOPLASMS; CARBOXYMETHYLCELLULOSE; CYTOKINES; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERFERON INDUCERS; INTERFERONS; INTERLEUKINS; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; POLYLYSINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70450199684     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.08.007     Document Type: Review

References (124)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 10 (2005) 987-996
2. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 9311 (2002) 1011-1018
3. Fine H.A., Dear K.B., Loeffler J.S., et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 8 (1993) 2585-2597
4. Kruger C., Greten T.F., and Korangy F. Immune-based therapies in cancer. Histol Histopathol 22 6 (2007) 687-696
5. Kushen M.C., Sonabend A.M., and Lesniak M.S. Current immunotherapeutic strategies for central nervous system tumors. Surg Oncol Clin N Am 16 4 (2007) 987-1004
6. Ksendzovsky A., Feinstein D., Zengou R., et al. Investigation of immunosuppressive mechanisms in a mouse glioma model. J Neurooncol 93 1 (2009) 107-114
7. Mitchell D.A., Fecci P.E., and Sampson J.H. Immunotherapy of malignant brain tumors. Immunol Rev 222 (2008) 70-100
8. Mahaley Jr. M.S., Aronin P.A., Michael A.J., et al. Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus Calmette-Guerin cell wall preparation. Surg Neurol 19 5 (1983) 453-455
9. Jaeckle K.A., Mittelman A., and Hill F.H. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. J Clin Onco 8 8 (1990) 1408-1418
10. Marras C., Mendola C., Legnani F.G., et al. Immunotherapy and biological modifiers for the treatment of malignant brain tumors. Curr Opin Oncol 15 3 (2003) 204-208
11. Constam D.B., Philipp J., Malipiero U.V., et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148 5 (1992) 1404-1410
12. Hao C., Parney I.F., Roa W.H., et al. Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol 103 2 (2002) 171-178
13. Zou J.P., Yamamoto N., Fujii T., et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 7 7 (1995) 1135-1145
14. Leonard J.P., Sherman M.L., Fisher G.L., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90 7 (1997) 2541-2548
15. Benedetti S., Bruzzone M.G., Pollo B., et al. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res 59 3 (1999) 645-652
16. Glick R.P., Lichtor T., Mogharbel A., et al. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41 4 (1997) 898-906 [discussion: 906-7]
17. Kikuchi T., Joki T., Abe T., et al. Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells. J Immunother 22 3 (1999) 245-250
18. Nagai M., and Arai T. Clinical effect of interferon in malignant brain tumours. Neurosurg Rev 7 1 (1984) 55-64
19. Packer R.J., Prados M., Phillips P., et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a children's cancer group phase I/II study. Cancer 77 10 (1996) 2150-2156
20. Piguet V., Carrel S., Diserens A.C., et al. Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones. J Natl Cancer Inst 76 2 (1986) 223-228
21. Yu J.S., Wei M.X., Chiocca E.A., et al. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 53 13 (1993) 3125-3128
22. Ehtesham M., Kabos P., Kabosova A., et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62 20 (2002) 5657-5663
23. Liu Y., Ehtesham M., Samoto K., et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 9 1 (2002) 9-15
24. Fathallah-Shaykh H.M., Zhao L.J., Kafrouni A.I., et al. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol 164 1 (2000) 217-222
25. Ehtesham M., Kabos P., Gutierrez M.A., et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 62 24 (2002) 7170-7174
26. Saleh M., Jonas N.K., Wiegmans A., et al. The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer. Gene Ther 7 20 (2000) 1715-1724
27. Lee J., Hampl M., Albert P., et al. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 4 4 (2002) 312-323
28. Kuppner M.C., Hamou M.F., Sawamura Y., et al. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg 71 2 (1989) 211-217
29. Siepl C., Bodmer S., Frei K., et al. The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T-cell growth without affecting the interaction of interleukin-2 with its receptor. Eur J Immunol 18 4 (1988) 593-600
30. Gansbacher B., Zier K., Daniels B., et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172 4 (1990) 1217-1224
31. Saris S.C., Rosenberg S.A., Friedman R.B., et al. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 69 1 (1988) 29-34
32. Barba D., Saris S.C., Holder C., et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70 2 (1989) 175-182
33. Vaquero J., Martinez R., Oya S., et al. Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma. Acta Neurochir [Wien] 98 (1989) 35-41
34. Merchant R.E., McVicar D.W., Merchant L.H., et al. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial. J Neurooncol 12 1 (1992) 75-83
35. Lesniak M.S., Sampath P., DiMeco F., et al. Comparative analysis of paracrine immunotherapy in experimental brain tumors. Neurosurg Focus 9 6 (2000) e4
36. Ewend M.G., Thompson R.C., Anderson R., et al. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J Immunother 23 4 (2000) 438-448
37. Sampath P., Hanes J., DiMeco F., et al. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 59 9 (1999) 2107-2114
38. Hanes J., Sills A., Zhao Z., et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18 7 (2001) 899-906
39. Colombo F., Barzon L., Franchin E., et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12 10 (2005) 835-848
40. Dillman R.O., Duma C.M., Schiltz P.M., et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27 5 (2004) 398-404
41. Giezeman-Smits K.M., Okada H., Brissette-Storkus C.S., et al. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 60 9 (2000) 2449-2457
42. Okada H., Giezeman-Smits K.M., Tahara H., et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther 6 2 (1999) 219-226
43. Benedetti S., Pirola B., Pollo B., et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6 4 (2000) 447-450
44. Benedetti S., Pirola B., Poliani P.L., et al. Dexamethasone inhibits the antitumor effect of interleukin-4 on rat experimental gliomas. Gene Ther 10 2 (2003) 188-192
45. Weiss J.M., Subleski J.J., Wigginton J.M., et al. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7 11 (2007) 1705-1721
46. DiMeco F., Rhines L.D., Hanes J., et al. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J Neurosurg 92 3 (2000) 419-427
47. Tahara H., Zitvogel L., Storkus W.J., et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154 12 (1995) 6466-6474
48. Kikuchi T., Akasaki Y., Abe T., et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27 6 (2004) 452-459
49. de Vries I.J., Eggert A.A., Scharenborg N.M., et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 25 5 (2002) 429-438
50. Herrlinger U., Kramm C.M., Johnston K.M., et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4 6 (1997) 345-352
51. Sedegah M., Weiss W., Sacci J.B.Jr., et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 164 11 (2000) 5905-5912
52. Yamanaka R. Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med 14 5 (2008) 228-235
53. Enderlin M., Kleinmann E.V., Struyf S., et al. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 16 2 (2009) 149-160
54. Villeneuve J., Tremblay P., and Vallieres L. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res 65 9 (2005) 3928-3936
55. Ali S., King G.D., Curtin J.F., et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 65 16 (2005) 7194-7204
56. Miller G., Pillarisetty V.G., Shah A.B., et al. Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. J Immunol 170 7 (2003) 3554-3564
57. Daga A., Orengo A.M., Gangemi R.M., et al. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer 121 8 (2007) 1756-1763
58. Lamprecht B., Kreher S., Anagnostopoulos I., et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112 8 (2008) 3339-3347
59. Brandes A.A., Scelzi E., Zampieri P., et al. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol 20 4 (1997) 364-367
60. Buckner J.C., Brown L.D., Kugler J.W., et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 82 3 (1995) 430-435
61. Rajkumar S.V., Buckner J.C., Schomberg P.J., et al. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys 40 2 (1998) 297-302
62. Yung W.K., Steck P.A., Kelleher P.J., et al. Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells. J Neurooncol 5 4 (1987) 323-330
63. Hiroishi K., Tuting T., Tahara H., et al. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Ther 6 12 (1999) 1988-1994
64. Buckner J.C., Schomberg P.J., McGinnis W.L., et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 92 2 (2001) 420-433
65. Olson J.J., McKenzie E., Skurski-Martin M., et al. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neurooncol 90 3 (2008) 293-299
66. Makar T.K., Wilt S., Dong Z., et al. IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system. J Interferon Cytokine Res 22 7 (2002) 783-791
67. Mahaley Jr. M.S., Dropcho E.J., Bertsch L., et al. Systemic beta-interferon therapy for recurrent gliomas: a brief report. J Neurosurg 71 5 Pt 1 (1989) 639-641
68. Allen J., Packer R., Bleyer A., et al. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors. J Clin Oncol 9 5 (1991) 783-788
69. Fetell M.R., Housepian E.M., Oster M.W., et al. Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study. Cancer 65 1 (1990) 78-83
70. Wakabayashi T., Kayama T., Nishikawa R., et al. A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol 38 10 (2008) 715-718
71. Sethna M.P., and Lampson L.A. Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatability antigen expression following intracerebral injection of interferon-gamma. J Neuroimmunol 34 (1991) 121-132
72. Glick R.P., Lichtor T., Kim T.S., et al. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36 3 (1995) 548-555
73. Ehtesham M., Samoto K., Kabos P., et al. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther 9 11 (2002) 925-934
74. Lichtor T., Glick R.P., Kim T.S., et al. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83 6 (1995) 1038-1044
75. Wolff J.E., Wagner S., Reinert C., et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 79 3 (2006) 315-321
76. Lotfi R., Schrezenmeier H., and Lotze M.T. Immunotherapy for cancer: promoting innate immunity. Front Biosci 14 (2009) 818-832
77. Ehrchen J.M., Sunderkotter C., Foell D., et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86 3 (2009) 557-566
78. Mariani C.L., Rajon D., Bova F.J., et al. Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective antitumor response in subcutaneous RG-2 gliomas. J Neurooncol 85 3 (2007) 231-240
79. Wolska A., Lech-Maranda E., and Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 14 2 (2009) 248-272
80. Tsan M.F. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 16 1 (2006) 32-37
81. Jack C.S., Arbour N., Manusow J., et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 175 7 (2005) 4320-4330
82. Ito A., Matsuoka F., Honda H., et al. Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles. Cancer Gene Ther 10 12 (2003) 918-925
83. Ito A., Shinkai M., Honda H., et al. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 52 2 (2003) 80-88
84. Kirsch M., Fischer H., and Schackert G. Activated monocytes kill malignant brain tumor cells in vitro. J Neurooncol 20 1 (1994) 35-45
85. Wu A., Oh S., Gharagozlou S., et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother 30 8 (2007) 789-797
86. Grauer O., Poschl P., Lohmeier A., et al. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J Neurooncol 82 2 (2007) 151-161
87. Carpentier A.F., and Meng Y. Recent advances in immunotherapy for human glioma. Curr Opin Oncol 18 6 (2006) 631-636
88. Meng Y., Carpentier A.F., Chen L., et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116 6 (2005) 992-997
89. Carpentier A.F., Xie J., Mokhtari K., et al. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6 6 (2000) 2469-2473
90. Carpentier A.F., Chen L., Maltonti F., et al. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59 21 (1999) 5429-5432
91. Carpentier A., Laigle-Donadey F., Zohar S., et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 8 1 (2006) 60-66
92. Talmadge J.E., Adams J., Phillips H., et al. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res 45 3 (1985) 1058-1065
93. Levy H.B., Lvovsky E., Riley F., et al. Immune modulating effects of poly ICLC. Ann N Y Acad Sci 350 (1980) 33-41
94. Hubbell H.R., Liu R.S., and Maxwell B.L. Independent sensitivity of human tumor cell lines to interferon and double-stranded RNA. Cancer Res 44 8 (1984) 3252-3257
95. Black P.L., Hartmann D., Pennington R., et al. Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I, C)-LC]. Int J Immunopharmacol 14 8 (1992) 1341-1353
96. Dick R.S., and Hubbell H.R. Sensitivities of human glioma cell lines to interferons and double-stranded RNAs individually and in synergistic combinations. J Neurooncol 5 4 (1987) 331-338
97. Rosenblum M.G., Yung W.K., Kelleher P.J., et al. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2′,5′-oligoadenylate synthetase and protein kinase activity. J Interferon Res 10 2 (1990) 141-151
98. Strayer D.R., Weisband J., Carter W.A., et al. Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferons. Am J Clin Oncol 10 4 (1987) 281-284
99. Droller M.J. Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid. J Urol 137 2 (1987) 202-206
100. Hawkins M.J., Levin L., and Borden E.C. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod 4 6 (1985) 664-668
101. Krown S.E., Kerr D., Stewart II W.E., et al. Phase I trials of poly(I, C) complexes in advanced cancer. J Biol Response Mod 4 6 (1985) 640-649
102. Nakamura O., Shitara N., Matsutani M., et al. Phase I-II trials of poly(ICLC) in malignant brain tumor patients. J Interferon Res 2 1 (1982) 1-4
103. Rettenmaier M.A., Berman M.L., and DiSaia P.J. Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose poly[ICLC]. Gynecol Oncol 24 3 (1986) 359-361
104. Theriault R.L., Hortobagyi G.N., Buzdar A.U., et al. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. Cancer Treat Rep 70 11 (1986) 1341-1342
105. Talmadge J.E., Herberman R.B., Chirigos M.A., et al. Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. J Immunol 135 4 (1985) 2483-2491
106. Ewel C.H., Urba W.J., Kopp W.C., et al. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res 52 11 (1992) 3005-3010
107. Black K.L., Chen K., Becker D.P., et al. Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. J Neurosurg 77 1 (1992) 120-126
108. Levy H.B. Historical overview of the use of polynucleotides in cancer. J Biol Response Mod 4 5 (1985) 475-480
109. Levy H.B., and Levine A.S. Antitumor effects of interferon and poly ICLC, and their possible utility as antineoplastic agents in man. Tex Rep Biol Med 41 (1981) 653-662
110. Matsumoto M., and Seya T. TLR3: Interferon induction by double-stranded RNA including poly(I: C). Adv Drug Deliv Rev 60 7 (2008) 805-812
111. Kim H., Yang E., Lee J., et al. Double-stranded RNA mediates interferon regulatory factor 3 activation and interleukin-6 production by engaging Toll-like receptor 3 in human brain astrocytes. Immunology 124 4 (2008) 480-488
112. Salazar A.M., Levy H.B., Ondra S., et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38 6 (1996) 1096-1103 [discussion: 1103-4]
113. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20 5 (2002) 1375-1382
114. Chong G., and Morse M.A. Combining cancer vaccines with chemotherapy. Expert Opin Pharmacother 6 16 (2005) 2813-2820
115. Wheeler C.J., Das A., Liu G., et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10 16 (2004) 5316-5326
116. van der Most R.G., Currie A., Robinson B.W., et al. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 66 2 (2006) 601-604
117. Zhu X., Nishimura F., Sasaki K., et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5 (2007) 10
118. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17 8 (1999) 2572-2578
119. Okada H., and Pollack I.F. Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4 10 (2004) 1609-1620
120. Selznick L.A., Shamji M.F., Fecci P., et al. Molecular strategies for the treatment of malignant glioma-genes, viruses, and vaccines. Neurosurg Rev 31 2 (2008) 141-155 [discussion: 155]
121. Sehgal A., and Berger M.S. Basic concepts of immunology and neuroimmunology. Neurosurg Focus 9 6 (2000) e1
122. Tanriover N., Ulu M.O., Sanus G.Z., et al. The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model. Neurol Res 30 5 (2008) 511-517
123. Grauer O.M., Molling J.W., Bennink E., et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 181 10 (2008) 6720-6729
124. Everson R.G., Graner M.W., Gromeier M., et al. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther 8 5 (2008) 717-732